A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Criteria

Inclusion Criteria:

• The subject was randomized into Study M06-855 and completed treatment in Periods 1 and 2 and the 2-week Extension Period

• If female, subject must be either postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least a method of birth control throughout the study

• If female, the result of a pregnancy tests are negative

• The subject is judged to be in generally good health

Exclusion Criteria:

• More than 7 days have elapsed since the last dose of study drug in Study M06-855

• The subject has taken any ADHD medication between the last dose of study drug in Study M06-855 and the first dose of study drug in the current study

• The subject anticipates a move outside the geographic area